Form 4: Omeros Corp Executive Peter B. Cancelmo Reports Stock Option Grant

VP, General Counsel of Omeros Corp, Peter B. Cancelmo, reports the acquisition of stock options.

Summary

• Peter B. Cancelmo, VP, General Counsel of Omeros Corp, filed a Form 4 on April 29, 2024.
• The report details a transaction on April 25, 2024, where Cancelmo acquired stock options.
• Cancelmo acquired options to buy 100,000 shares of Omeros Corp common stock at an exercise price of $3.06.
• The options vest in 48 equal monthly installments starting April 1, 2024, and expire on April 25, 2034.
• Following the transaction, Cancelmo directly owns derivative securities for 100,000 shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation. It is neither particularly positive nor negative.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 48 months is a typical vesting period for stock options.
• Comparing the size of the grant to similar roles at comparable companies (e.g., Amgen, Biogen) would provide further context.

Stakeholder Impact

• The granting of stock options can incentivize management to improve company performance, potentially benefiting shareholders.
• The dilution effect of potential future share issuance upon option exercise is a consideration for existing shareholders.

Key Dates